When TP53-mutated clones appear during the disease course would be important to determine, as their early detection in myeloid malignancies could allow to target them pharmacologically, potentially preventing progression to full-blown biallelic TP53 MDS/AML. Here, TP53 is linked to myelodysplastic syndrome.